Can Oral Ozempic and Label Expansions Revive NVO's Near-Term Growth? [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
tablet) for type II diabetes (T2D), and Wegovy (injection and oral tablet) for chronic weight management. Though NVO has been able to bring the compounded alternatives problem under control with help from the FDA and strategic deals with telehealth companies, it still faces mounting structural challenges, as evidenced by its 2026 outlook, which highlights weak core momentum. Adjusted guidance points to declines in sales and operating profit, as pricing pressure, rising competition from arch-rival Eli Lilly LLY and slowing U.S. demand weigh on performance. While international growth and the launch of oral Wegovy offer some support, increased costs and lack of one-off benefits limit upside, leaving investors doubtful about Novo Nordisk's ability to sustain its leadership in the evolving obesity market. Amid intensifying competition, Novo Nordisk is working to broaden its cardiometabolic portfolio, aiming to expand the eligible patient base, which is expected to drive higher sales vo
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Is Novo Nordisk (CPSE:NOVO B) Pricing Reflect Its Recent Share Price Swings And Growth Outlook [Yahoo! Finance]Yahoo! Finance
- Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Rare Disease Wins Add Context To Undervalued Share Price [Yahoo! Finance]Yahoo! Finance
- Is This Deal a Game Changer for Novo Nordisk? [Yahoo! Finance]Yahoo! Finance
- Is This Deal a Game Changer for Novo Nordisk? [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/27/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- NVO's page on the SEC website